[High-dose-rate brachytherapy with external beam radiotherapy for localized or locally advanced prostate cancer].
OBJECTIVE
To evaluate the therapeutic outcomes and late toxicities in patients treated by high-dose-rate brachytherapy (HDR-BT) with external beam radiotherapy (EBRT) for localized or locally advanced prostate cancer.


METHODS
From May 2004 to September 2008, 86 men were treated by HDR-BT with EBRT for localized or locally advanced prostate cancer at the National Hospital Organization Kyushu Medical center. The median EBRT and HDR-BT doses were 40 Gy and 30 Gy, respectively.


RESULTS
With a median follow-up of 24 months, the 3-year overall, disease specific, and biochemical relapse-free survival rates in all patients were 97.3%, 100%, and 83.6% respectively. The 3-year biochemical relapse-free survival rate of the patients categorized to low or intermediate risk group (91.8%) was significantly better than that of the patients categorized to the high risk group (74.3%) (p = 0.042). There was no significant difference of biochemical relapse-free survival regarding to the other clinical factors (age, T-stage, Gleason score, initial prostate-specific antigen level, neoadjuvant hormone therapy, and total dose of EBRT and HDR-BT). Late Grade2 and Grade3 gastrointestinal toxicities were observed in 8 patients (9.3%) and 2 patients (2.3%), respectively. Late Grade2 genitourinary toxicities were observed in 12 patients (13.9%). There was no patient suffered from late Grade3 or greater genitourinary toxicities.


CONCLUSIONS
HDR-BT with EBRT can be safe and effective for localized or locally advanced prostate cancer.
Matsunobu
Akira
A
Department of Radiology, National Hospital Organization Fukuoka Higashi Medical Center, Japan.
Shioyama
Yoshiyuki
Y
Uehara
Satoru
S
Ohga
Saiji
S
Atsumi
Kazushige
K
Matsumura
Taisei
T
Sakamoto
Naotaka
N
Yoshikawa
Masahiro
M
Iguchi
Atsushi
A
Honda
Hiroshi
H
D000368:Aged; D001918:Brachytherapy / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011879:Radiotherapy Dosage